Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer.

Cancer science - 1 Apr 2024

Lee Mi Rim, Woo Sang Myung, Kim Min Kyeong, Han Sung-Sik, Park Sang-Jae, Lee Woo Jin, Lee Dong-Eun, Choi Sun Il, Choi Wonyoung, Yoon Kyong-Ah, Chun Jung Won, Kim Yun-Hee, Kong Sun-Young

Abstract excerpt

Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in circulating tumor deoxyribonucleic acid (ctDNA) have been reported as representative noninvasive prognostic markers for pancreatic ductal adenocarcinoma (PDAC). Here, we aimed to evaluate single KRAS mutations as prognostic and predictive biomarkers, with an emphasis on potential therapeutic approaches to PDAC. A total of 128 patients were analyzed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Mutation

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 38348576
DOI: 10.1111/cas.16104
PMCID: PMC11007020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer.PMID 38348576Read ↗

Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.Semantic proximity Read ↗

Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.Semantic proximity Read ↗

Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer.Semantic proximity Read ↗

Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study.Semantic proximity Read ↗

Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicenter Cohort Study.Semantic proximity Read ↗

Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.Semantic proximity Read ↗

Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer.Semantic proximity Read ↗

Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.Semantic proximity Read ↗

High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.Semantic proximity Read ↗

Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer.Semantic proximity Read ↗

KRAS Mutant Allele Fraction in Circulating Cell-Free DNA Correlates With Clinical Stage in Pancreatic Cancer PatientsSemantic proximity Read ↗

Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.